Bard Finally Paid Damages in First Avaulta Transvaginal Mesh Case
C.R. Bard finally exhausted its appeals in the first case to go to trial involving its Avaulta transvaginal mesh product. The jury awarded plantiff Christine Scott $5.5M, split 60/40 between Bard and the operating surgeon. Bard immediately appealed. The last chance for reversal came in February 2015 and Bard broke out the checkbook in March. This was kept quiet; a reporter following the case discovered the payment by reviewing Bard’s public SEC investor reports.